Abiopharma

🔍 Langlais Kerri M. (Director)

Company: TERAWULF INC. (WULF)

Report Date: 2026-08-01

Detailed Transactions and Holdings:

• Acquired 500,000 shares of Common stock, $0.001 par value per share (Direct)
  Date: 2026-08-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,656,881.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 276,500 shares of Common stock, $0.001 par value per share (Direct)
  Date: 2026-08-03 | Code: D | equity_swap_involved: 0 | shares_owned_after: 4,380,381.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common stock, $0.001 par value per share (Direct)
  Date: 2026-08-01 | Code: H | nature_of_ownership: By Langlais Family 2021 GST Trust | shares_owned_after: 864,701.00
• Sold 500,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,000,000.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4

Footnotes:

• F1: The Reporting Person received restricted stock units which vested in accordance with their terms upon the first anniversary of August 1, 2025, as reflected in this Form 4, subject to the Reporting Person's continued employment or service with the Issuer through such date.
• F2: The disposition is due to withholding to cover taxes, as a result of the Reporting Person's election of net settlement with regard to the vesting of restricted stock units, which vested on August 1, 2026, as reflected in this Form 4.
• F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, $0.001 par value per share.
• F4: The restricted stock units vested upon the first anniversary of August 1, 2025, subject to the Reporting Person's continued employment or service with the Issuer through such date. The remaining restricted stock units will vest ratably upon the second and third anniversaries of August 1, 2025, respectively, subject to the Reporting Person's continued employment or service with the Issuer through each such date.